- Pharma Intelligence Award Japan 2022 Commemorative Webinar “PPI Inhibition by Small Molecules: A New Drug Discovery Paradigm”
- PRISM Biolab Wins Biotech Company of the Year Award of Informa Pharma Intelligence Award 2022
- PRISM BioLab, enters multi-project drug discovery collaboration with Roche and Genentech
PRISM BioLab is committed to maximizing the potential of its PepMetics® Technology, transforming the “undruggable” to “druggable” with the aim of finding cures for the incurable.
PRISM BioLab is a biotechnology company with PepMetics Technology, a proprietary drug discovery platform. PepMetics Molecules are designed to mimic α-helix or β-turn peptides using unique, stable scaffolds.
We synthesize like a small molecule, but our PepMetic Molecules act like peptides.